Mounjaro Didn't Work for Me: What Could Be Going On

Step 1: Work out where in the process things went wrong

The first thing worth establishing is how long you were on treatment and at which dose. Tirzepatide starts at 2.5 mg, a dose that exists largely to let your system adjust gradually rather than to produce significant weight loss. Many people spend four weeks there, move to 5 mg, and still feel underwhelmed, which is entirely expected. The dose at which appetite suppression becomes pronounced is usually 7.5 mg or above, and some people only find their therapeutic point at 10 mg or higher.

If Mounjaro didn't work for you within the first eight to twelve weeks, it may simply be that you hadn't yet reached a dose that does the job. That's a different problem from the medicine failing you at its full licensed dose. Our page on why Mounjaro isn't working goes deeper into this dose-response picture.

It's also worth being honest with yourself (and your prescriber) about whether nausea or other side effects caused you to stall at a lower dose, or to eat less consistently. That isn't failure; it's information that shapes what comes next.

Step 2: Consider what else might have been working against it

Tirzepatide acts on two gut-hormone pathways to reduce appetite and slow how quickly the stomach empties. But several factors can dampen that effect in practice. Certain medicines, including some antidepressants, antipsychotics, and corticosteroids, are associated with weight gain or reduced response to appetite-regulating treatments. If you're taking any of these, that interaction is worth raising directly with your prescriber.

Underlying health conditions matter too. Untreated hypothyroidism, insulin resistance, polycystic ovary syndrome, and sleep disorders can all make weight loss harder regardless of the medicine involved. If any of these were undiagnosed or poorly controlled during your treatment, they may account for a weaker-than-expected response.

Diet composition also plays a role. Tirzepatide reduces hunger, but it doesn't neutralise the effect of highly palatable, calorie-dense foods that are easy to eat past fullness. The profile of people who tend to see a smaller response to tirzepatide includes those whose eating patterns didn't shift much alongside the medicine. The NHS guidance on tirzepatide for weight management is clear that the medicine works alongside a reduced-calorie diet and increased physical activity, not instead of them.

Step 3: Think about whether the definition of "not working" is accurate

This sounds blunt, but it matters. A common reason people feel Mounjaro didn't work is that their expectation was set by the headline trial figure, around 20% average body-weight reduction at the 15 mg dose in SURMOUNT-1, as reported in the New England Journal of Medicine. What that average conceals is the range: some participants lost considerably more, some considerably less, and a minority lost very little. You may be in the lower part of that distribution without the treatment having failed outright.

Equally, weight loss on tirzepatide is not linear. Losses are often fastest in the first few months, then slow as the body adapts. A plateau after initial progress is not the same as the medicine stopping work. Our prescribers hear this regularly, and the answer is almost always a conversation about dose, timeline, and what's changed in the person's life rather than an immediate switch.

If you're weighing up whether tirzepatide is the right fit, the page on whether Mounjaro is likely to work for you covers the clinical predictors in more detail. For a broader look at how the medicine works, the tirzepatide overview and our main Mounjaro page both explain the dual GIP and GLP-1 mechanism that underpins it.

Step 4: Know when to ask for a clinical review rather than a second guess

If you've been at the highest dose you can tolerate for at least twelve weeks, without meaningful progress and with reasonable lifestyle changes in place, that's the moment for a structured prescriber review rather than perseverance alone. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose. Your prescriber may look at alternative doses, explore whether an underlying condition needs addressing, or discuss whether a different treatment pathway makes more sense.

We understand this is a frustrating place to be. When something you hoped would help hasn't delivered, it takes a toll. That's a real experience, and it deserves a thorough clinical conversation, not a shrug. Our weight-loss treatment overview sets out the options available, and you can explore pricing context on our treatment page if you're considering a fresh start with proper clinical support. You're also welcome to look at why Mounjaro doesn't work for some people for a fuller breakdown of the evidence behind non-response.